In another win for CGRP inhibitors, Eli Lilly's galcanezumab cut monthly headache days in three phase III trials -- two in episodic and one in chronic migraine, .
Full details from the EVOLVE 1 & 2 studies and the REGAIN study were presented at the American Headache Society meeting in Boston last weekend, following top-line results reported in May.
For episodic migraine, the 120-mg and 240-mg doses cut the average number of monthly headache days by 4 and 3.8 days in one study and 3.7 days and 3.6 days in another, compared with 1.85 and 2.15 days with placebo. In chronic migraine, the 240-mg dose cut the number of migraine days by 2.1 days compared with placebo.
Other drugs in the CGRP inhibitor class include Amgen's erenumab, Alder's eptinezumab, and Teva's fremanezumab.